Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 4/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | OGA | O60502 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 6/20 | 0.34 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | HSD11B2 | P80365 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19012353 | 0.87 | SMO (0.39) | SMOHRH3OGAHDAC11CNR1 | |
| SCHEMBL18436688 | 0.78 | SMO (0.39) | SMOHRH3OGAHSD11B1HDAC11 | |
| SCHEMBL19001112 | 0.76 | OGA (0.54) | SMOHRH3OGAHSD11B1HSD11B2 | |
| SCHEMBL19012378 | 0.72 | OGA (0.51) | SMOHRH3OGAHSD11B1HSD11B2 | |
| SCHEMBL19012379 | 0.70 | OGA (0.46) | SMOHRH3OGAHSD11B1HSD11B2 | |
| SCHEMBL19012358 | 0.69 | SMO (0.47) | SMOHRH3OGAHSD11B1HSD11B2 | |
| SCHEMBL19001111 | 0.69 | HRH3 (0.39) | SMOHRH3OGAHSD11B1CNR2 | |
| SCHEMBL19012361 | 0.69 | SGPL1 (0.40) | SMOHRH3OGA | |
| SCHEMBL18436094 | 0.69 | OGA (0.44) | SMOHRH3OGAHSD11B1HSD11B2 | |
| SCHEMBL21336772 | 0.69 | OGA (0.47) | SMOHRH3OGAHSD11B1HSD11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9938292-B2 | Quinoline derivatives as SMO inhibitors | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2018-04-10 | — | — | US | disclosed |
| US-9938292-B2 | Quinoline derivatives as SMO inhibitors | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2018-04-10 | — | — | US | disclosed |
| US-20170174703-A1 | QUINOLINE DERIVATIVES AS SMO INHIBITORS | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2017-06-22 | — | — | US | disclosed |
| US-20170174703-A1 | QUINOLINE DERIVATIVES AS SMO INHIBITORS | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174703-A1 | QUINOLINE DERIVATIVES AS SMO INHIBITORS | SMO, GLI1, SHH | SMO 1/4885HRH3 321/4885OGA 2474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.